Clinical trials: Breast Cancer, Estrogen Receptor-Positive
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
This phase II trial is studying how well giving hormone therapy together with combination chemotherapy before and after surgery works in treating patients with stage I-IIIA breast cancer.
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer
- Trial name
- NCT00194792
- Testing
- exemestane, triptorelin pamoate, capecitabine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
Breast Cancer
Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer
RATIONALE: Ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cancer cell growth. Studying samples of blood and tissue from patients with breast cancer in the laboratory may help doctors learn…
- Trial name
- NCT01009437
- Testing
- ritonavir, therapeutic conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Metastatic Breast Cancer, Breast Cancer Stage I
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
This is a Study to Evaluate the Efficacy and Safety of Multiple Combination Therapies with FWD1802 in Subjects with ER-positive/HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Locally Advanced Breast Cancer (LABC)
- Trial name
- NCT07002177
- Testing
- FWD1802, Palbociclib 125mg, Ribociclib 200Mg Oral Tablet
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Forward Pharmaceuticals Co., Ltd.
Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
This clinical trial studies use of F-18 16 alpha-fluoroestradiol ([F-18] FES) positron emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted…
- Conditions
- Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT04692103
- Testing
- F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Computed Tomography
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Breast Cancer
Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers
This study evaluates the addition of Ki-67, Oncotype DX and MRI in the treatment of early stage breast cancer with neoadjuvant treatment. All enrolled patients will have Ki-67 and Oncotype AND/OR an MRI before and after surgery.
- Trial name
- ER (NCT03790813)
- Testing
- Intervention 1, Intervention 2
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer, Estrogen Receptor Positive Tumor
Characterization of Biophysical and Mechanical Parameters on Skin of Breast Cancer Patients
Aim of this study is to characterize the chemical/physical and structural parameters of the skin in patients with breast cancer undergoing oncological adjuvant treatment in order to understand how to prevent and manage adverse…
- Trial name
- NCT06474988
- Testing
- Skin tests
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- European Institute of Oncology
Breast Cancer
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
The investigators propose to conduct a Phase I/randomized Phase II study design in order to test the tolerability and efficacy of AZD0530 (also called saracatinib) when used together with anastrozole in therapy for ER+ and/or…
- Trial name
- NCT01216176
- Testing
- Anastrozole, AZD0530 (saracatinib)
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Joyce Marie Slingerland, MD
Breast Neoplasm, Chemotherapy Effect
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
This is a multicenter phase 2 study evaluating the efficacy and safety of trifluridine/tipiracil in women with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.
- Trial name
- TIBET (NCT04489173)
- Testing
- trifluridine/tipiracil
- Where
- 10 sites in Netherlands
- Volunteers
- 52 people
- Sponsor
- Borstkanker Onderzoek Groep
Post Menopausal, Hormone Receptor Positive Breast Cancer
A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer
In this study the investigators want to find out about the effects of this drug in women with metastatic breast cancer. The study has two major parts; dose escalation and dose expansion.
- Trial name
- NCT01808040
- Testing
- TAK700
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Wisconsin, Madison
Unresectable or Metastatic Breast Cancer
Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
This is a multicenter, open phase Ib/II clinical study, which is divided into two phases: dose exploration and efficacy expansion.
- Trial name
- NCT06167694
- Testing
- HRS-8080; Dalpiciclib Isethionate Tablets
- Where
- 2 sites in China
- Volunteers
- 146 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Breast Cancer
A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer
Around 75% of breast cancers are defined and driven by Oestrogen receptor alpha (ERα) transcriptional activity. Standard treatment is endocrine therapy however clinical outcomes vary considerably, and a proportion of women with…
- Trial name
- PIONEER (NCT03306472)
- Testing
- Megestrol Acetate 40 MG, Megestrol Acetate 160 MG, Letrozole
- Where
- United Kingdom
- Volunteers
- 198 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Estrogen Receptor Positive Breast Cancer
A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer
This is an open-label, multicentre, 4-arm randomised phase II trial of fulvestrant + AZD2014 versus fulvestrant + everolimus versus fulvestrant alone in patients with ER-positive, HER2-negative advanced or metastatic breast…
- Trial name
- MANTA (NCT02216786)
- Testing
- AZD2014, Everolimus, Fulvestrant
- Where
- 79 sites in France, Georgia and 7 more
- Volunteers
- 333 people
- Sponsor
- Queen Mary University of London
Breast Neoplasm
Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography
The primary objective of this study is to determine the correlation between the distribution of F-18 FES within ER+ breast tumors as seen on Positron Emission Mammography (PEM) images of the breast, and the distribution of cells…
- Trial name
- PEM-FES (NCT03266562)
- Testing
- F-18 FES, F-18 FDG
- Where
- United States
- Sponsor
- Mayo Clinic
Microsatellite Stable Colorectal Carcinoma, Platinum Resistant Epithelial Ovarian Cancer Type II
Study of Azacitidine and Durvalumab in Advanced Solid Tumors
This is a phase 2 study of investigational drug, durvalumab given in combination with azacitidine (CC-486). The main purpose of this phase 2 study is to assess the antitumor activity of azacitidine in combination with durvalumab…
- Conditions
- Microsatellite Stable Colorectal Carcinoma, Platinum Resistant Epithelial Ovarian Cancer Type II, Estrogen Receptor Positive and HER2 Negative Breast Cancer
- Trial name
- METADUR (NCT02811497)
- Testing
- Azacitidine, Durvalumab
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- University Health Network, Toronto
Metastatic Breast Cancer
Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC
This is an international, open-label, non-controlled, multicenter phase II clinical trial with two different primary objectives: a biological and a clinical objective.
- Trial name
- BioPER (NCT03184090)
- Testing
- Palbociclib, Endocrine therapy (non IMP)
- Where
- 15 sites in Italy, Spain
- Volunteers
- 33 people
- Sponsor
- MedSIR
Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
This randomized phase II trial studies how well fulvestrant works with or without bortezomib in treating patients with estrogen receptor positive breast cancer that has spread to other places in the body and cannot be removed by…
- Conditions
- Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT01142401
- Testing
- Bortezomib, Fulvestrant, Laboratory Biomarker Analysis
- Where
- 21 sites in United States
- Volunteers
- 118 people
- Sponsor
- National Cancer Institute (NCI)
Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA
The purpose of the study is to determine the diagnostic role of ctDNA when used to monitor metastatic breast cancer (MBC) during first-line endocrine therapy.
- Conditions
- Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms, Neoplasms, Breast, Breast Diseases
- Trial name
- MAGNETIC1 (NCT05814224)
- Testing
- Liquid biopsy and CT scan
- Where
- 7 sites in Italy
- Volunteers
- 164 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Breast Cancer, Infertility
Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Goserelin may help prevent early menopause in patients undergoing chemotherapy for breast cancer. It is not yet known whether goserelin is effective in preventing early menopause in women undergoing chemotherapy for…
- Conditions
- Breast Cancer, Infertility, Menopausal Symptoms
- Trial name
- NCT00427245
- Testing
- cyclophosphamide, goserelin acetate, adjuvant therapy
- Where
- 66 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- Anglo Celtic Cooperative Oncology Group
ER+ HER2- Advanced Breast Cancer
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)
- Trial name
- SERENA-1 (NCT03616587)
- Testing
- AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus
- Where
- 17 sites in United States, Spain and 1 more
- Volunteers
- 396 people
- Sponsor
- AstraZeneca
Breast Adenocarcinoma, Estrogen Receptor Positive
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
This phase I/II trial studies the side effects and the best dose of triciribine phosphate when given together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide and to see how well they work in treating patients…
- Conditions
- Breast Adenocarcinoma, Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma
- Trial name
- NCT01697293
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Prescient Therapeutics, Ltd.